Construction begins on new Dutch research reactor

The Netherlands has officially commenced construction of the Pallas research reactor in Petten, a €2 billion project set to replace the ageing High Flux Reactor, operational since 1960. The facility is crucial for producing medical isotopes used in diagnostics and treatments, supplying 60 per cent of Europe’s and 30 per cent of the world’s demand.

NRG-Pallas CEO Maurits Wolleswinkel emphasised that the reactor will improve efficiency and reliability in isotope production, reducing Europe’s dependence on foreign suppliers. The project also aims to support the development of new therapeutic isotopes, enhancing patient care across the continent.

Programme director Peter Dijk highlighted the scale and complexity of the project. Preparatory works—including the construction pit and foundation—have been completed, and early work on the secondary cooling system and cooling water pipeline is underway. The reactor will operate with a “tank-in-pool” design and a thermal power of approximately 55 MW, optimising neutron flux deployment compared with its predecessor.

The Dutch government has committed long-term funding, and the European Commission approved the plan under EU state aid rules. This follows careful coordination with construction partner FCC and design partner ICHOS, ensuring the state-owned company is fully prepared to deliver the project efficiently.

Once operational, the Pallas reactor will strengthen Europe’s independence in medical isotope production while supporting advancements in diagnostic and therapeutic treatments.

Explore the full article on Europe’s next-generation medical reactor project.